BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Itkonen MK, Tornio A, Lapatto-Reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel. Clin Pharmacol Ther 2019;105:219-28. [PMID: 29696643 DOI: 10.1002/cpt.1099] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Hodge C, Marra F, Marzolini C, Boyle A, Gibbons S, Siccardi M, Burger D, Back D, Khoo S. Drug interactions: a review of the unseen danger of experimental COVID-19 therapies. J Antimicrob Chemother 2020;75:3417-24. [PMID: 32750131 DOI: 10.1093/jac/dkaa340] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
2 Cattaneo D, Cossu MV, Rizzardini G. Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV. Expert Opin Drug Metab Toxicol 2019;15:927-35. [PMID: 31668105 DOI: 10.1080/17425255.2019.1685495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lee CH, Franchi F, Angiolillo DJ. Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol 2020;16:1079-96. [PMID: 32835535 DOI: 10.1080/17425255.2020.1814254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
4 Marzolini C, Livio F. Prescribing issues in elderly individuals living with HIV. Expert Rev Clin Pharmacol 2019;12:643-59. [PMID: 31155978 DOI: 10.1080/17512433.2019.1627200] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
5 Gerotziafas GT, Catalano M, Colgan MP, Pecsvarady Z, Wautrecht JC, Fazeli B, Olinic DM, Farkas K, Elalamy I, Falanga A, Fareed J, Papageorgiou C, Arellano RS, Agathagelou P, Antic D, Auad L, Banfic L, Bartolomew JR, Benczur B, Bernardo MB, Boccardo F, Cifkova R, Cosmi B, De Marchi S, Dimakakos E, Dimopoulos MA, Dimitrov G, Durand-Zaleski I, Edmonds M, El Nazar EA, Erer D, Esponda OL, Gresele P, Gschwandtner M, Gu Y, Heinzmann M, Hamburg NM, Hamadé A, Jatoi NA, Karahan O, Karetova D, Karplus T, Klein-Weigel P, Kolossvary E, Kozak M, Lefkou E, Lessiani G, Liew A, Marcoccia A, Marshang P, Marakomichelakis G, Matuska J, Moraglia L, Pillon S, Poredos P, Prior M, Salvador DRK, Schlager O, Schernthaner G, Sieron A, Spaak J, Spyropoulos A, Sprynger M, Suput D, Stanek A, Stvrtinova V, Szuba A, Tafur A, Vandreden P, Vardas PE, Vasic D, Vikkula M, Wennberg P, Zhai Z; Scientific Reviewer Committee. Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine. Thromb Haemost 2020;120:1597-628. [PMID: 32920811 DOI: 10.1055/s-0040-1715798] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 21.0] [Reference Citation Analysis]
6 Kahma H, Filppula AM, Launiainen T, Viinamäki J, Neuvonen M, Evangelista EA, Totah RA, Backman JT. Critical Differences between Enzyme Sources in Sensitivity to Detect Time-Dependent Inactivation of CYP2C8. Drug Metab Dispos 2019;47:436-43. [PMID: 30709838 DOI: 10.1124/dmd.118.085498] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Ferrari F, Martins VM, Teixeira M, Santos RD, Stein R. COVID-19 and Thromboinflammation: Is There a Role for Statins? Clinics (Sao Paulo) 2021;76:e2518. [PMID: 33787678 DOI: 10.6061/clinics/2021/e2518] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Tornio A, Filppula AM, Backman JT. Translational aspects of cytochrome P450-mediated drug-drug interactions: A case study with clopidogrel. Basic Clin Pharmacol Toxicol 2021. [PMID: 34410044 DOI: 10.1111/bcpt.13647] [Reference Citation Analysis]
9 Ribes A, Vardon-Bounes F, Mémier V, Poette M, Au-Duong J, Garcia C, Minville V, Sié P, Bura-Rivière A, Voisin S, Payrastre B. Thromboembolic events and Covid-19. Adv Biol Regul 2020;77:100735. [PMID: 32773098 DOI: 10.1016/j.jbior.2020.100735] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 10.5] [Reference Citation Analysis]
10 Khadankhuu B, Fei Y, Xu D, Li Y, Hou K, Li F, Fang W, Chen X, Li Y. Pharmacokinetics and pharmacodynamics analysis of XQ-1H and its combination therapy with clopidogrel on cerebral ischemic reperfusion injury in rats. J Pharm Biomed Anal 2020;179:112975. [PMID: 31735472 DOI: 10.1016/j.jpba.2019.112975] [Reference Citation Analysis]
11 Di Paolo V, Ferrari FM, Poggesi I, Quintieri L. A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition. Expert Opin Drug Metab Toxicol 2021;:1-8. [PMID: 34720033 DOI: 10.1080/17425255.2021.1998453] [Reference Citation Analysis]
12 Shebley M. Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test? Clin Pharmacol Ther 2019;105:320-1. [PMID: 30225892 DOI: 10.1002/cpt.1196] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
13 Dhakal BP, Sweitzer NK, Indik JH, Acharya D, William P. SARS-CoV-2 Infection and Cardiovascular Disease: COVID-19 Heart. Heart Lung Circ 2020;29:973-87. [PMID: 32601020 DOI: 10.1016/j.hlc.2020.05.101] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 16.5] [Reference Citation Analysis]
14 Varma MV, Bi Y, Lazzaro S, West M. Clopidogrel as a Perpetrator of Drug–Drug Interactions: A Challenge for Quantitative Predictions? Clin Pharmacol Ther 2019;105:1295-9. [DOI: 10.1002/cpt.1398] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
15 Loer HLH, Türk D, Gómez-mantilla JD, Selzer D, Lehr T. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions. Pharmaceutics 2022;14:915. [DOI: 10.3390/pharmaceutics14050915] [Reference Citation Analysis]
16 Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, Brown TS, Der Nigoghossian C, Zidar DA, Haythe J, Brodie D, Beckman JA, Kirtane AJ, Stone GW, Krumholz HM, Parikh SA. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Cardiol 2020;75:2352-71. [PMID: 32201335 DOI: 10.1016/j.jacc.2020.03.031] [Cited by in Crossref: 960] [Cited by in F6Publishing: 863] [Article Influence: 480.0] [Reference Citation Analysis]
17 Bikdeli B, Madhavan MV, Gupta A, Jimenez D, Burton JR, Der Nigoghossian C, Chuich T, Nouri SN, Dreyfus I, Driggin E, Sethi S, Sehgal K, Chatterjee S, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Bertoletti L, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Tafur AJ, Francese DP, Batra J, Falanga A, Clerkin KJ, Uriel N, Kirtane A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Leon MB, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group. Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thromb Haemost 2020;120:1004-24. [PMID: 32473596 DOI: 10.1055/s-0040-1713152] [Cited by in Crossref: 99] [Cited by in F6Publishing: 95] [Article Influence: 49.5] [Reference Citation Analysis]
18 Chetty M, Ravenstijn P, Manchandani P. Clopidogrel Dosing: Current Successes and Emerging Factors for Further Consideration. Clin Pharmacol Ther 2021;109:1203-11. [PMID: 32970826 DOI: 10.1002/cpt.2055] [Reference Citation Analysis]
19 Itkonen MK, Tornio A, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans. Drug Metab Dispos 2019;47:377-85. [DOI: 10.1124/dmd.118.084665] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Cohoon KP, Mahé G, Tafur AJ, Spyropoulos AC. Emergence of institutional antithrombotic protocols for coronavirus 2019. Res Pract Thromb Haemost 2020;4:510-7. [PMID: 32542211 DOI: 10.1002/rth2.12358] [Cited by in Crossref: 27] [Cited by in F6Publishing: 33] [Article Influence: 13.5] [Reference Citation Analysis]
21 Venkatakrishnan K, Rostami‐hodjegan A. Come Dance With Me: Transformative Changes in the Science and Practice of Drug–Drug Interactions. Clin Pharmacol Ther 2019;105:1272-8. [DOI: 10.1002/cpt.1433] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
22 Askin L, Tanrıverdi O, Askin HS. The Effect of Coronavirus Disease 2019 on Cardiovascular Diseases. Arq Bras Cardiol 2020;114:817-22. [PMID: 32491073 DOI: 10.36660/abc.20200273] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 6.5] [Reference Citation Analysis]
23 Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quéré I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH; Global COVID-19 Thrombosis Collaborative Group, Endorsed by the ISTH, NATF, ESVM, and the IUA, Supported by the ESC Working Group on Pulmonary Circulation and Right Ventricular Function. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol 2020;75:2950-73. [PMID: 32311448 DOI: 10.1016/j.jacc.2020.04.031] [Cited by in Crossref: 1202] [Cited by in F6Publishing: 1150] [Article Influence: 601.0] [Reference Citation Analysis]
24 Guha S, Mukhopadhay S, Karak A, Choudhury B, Kapoor A, Yadav R. Managing ACS during COVID-19 infection: Do not follow the traditional route. Indian Heart J 2020;72:128-30. [PMID: 32534687 DOI: 10.1016/j.ihj.2020.04.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
25 Manolis AS, Manolis TA, Manolis AA, Melita H. Cardiovascular implications and complications of the coronavirus disease-2019 pandemic: a world upside down. Curr Opin Cardiol 2021;36:241-51. [PMID: 33395080 DOI: 10.1097/HCO.0000000000000838] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
26 Okpara IC, Oghagbon EK. Mitigating the Risk of COVID-19 Deaths in Cardiovascular Disease Patients in Africa Resource Poor Communities. Front Cardiovasc Med 2021;8:626115. [PMID: 33665211 DOI: 10.3389/fcvm.2021.626115] [Reference Citation Analysis]
27 Nappi F, Iervolino A, Avtaar Singh SS. Thromboembolic Complications of SARS-CoV-2 and Metabolic Derangements: Suggestions from Clinical Practice Evidence to Causative Agents. Metabolites 2021;11:341. [PMID: 34070672 DOI: 10.3390/metabo11060341] [Reference Citation Analysis]
28 Agarwal S, Agarwal SK. Lopinavir-Ritonavir in SARS-CoV-2 Infection and Drug-Drug Interactions with Cardioactive Medications. Cardiovasc Drugs Ther 2021;35:427-40. [PMID: 32918656 DOI: 10.1007/s10557-020-07070-1] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. J Int AIDS Soc 2020;23:e25449. [PMID: 32011104 DOI: 10.1002/jia2.25449] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 11.5] [Reference Citation Analysis]
30 McGovern R, Conway P, Pekrul I, Tujjar O. The Role of Therapeutic Anticoagulation in COVID-19. Case Rep Crit Care 2020;2020:8835627. [PMID: 32908713 DOI: 10.1155/2020/8835627] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
31 Soeiro AM, Leal TCAT, Pereira MP, Lima EG, Figueiredo ACBDS, Petriz JLF, Precoma DB, Serrano CV Jr. Position Statement on the Use of Antiplatelet Agents and Anticoagulants in Patients Infected with the New Coronavirus (COVID-19) - 2020. Arq Bras Cardiol 2020;115:292-301. [PMID: 32876200 DOI: 10.36660/abc.20200424] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Itkonen MK, Tornio A, Lapatto‐reiniluoto O, Neuvonen M, Neuvonen PJ, Niemi M, Backman JT. Response to “Interaction of Dasabuvir With Clopidogrel: Did Predictions by Physiologically Based Pharmacokinetics Modeling Pass the Test?”. Clin Pharmacol Ther 2018;105:322-322. [DOI: 10.1002/cpt.1195] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]